Skip to content

Incyte INCY Price / book

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Pfizer logo
PfizerPFE
1.8×+0.2×
Gilead Sciences logo
Gilead SciencesGILD
7.4×+0.1×
Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
Amgen logo
AmgenAMGN
20.6×-6.3×
Biogen logo
BiogenBIIB
1.4×+0.3×

Other financials

Income statement

See full
Revenue$1.3B+20.9%
Gross profit$1.2B+19.2%
Operating income$301.1M+46.8%
Net income$303.3M+91.7%
EPS (diluted)$1.47+83.8%

Balance sheet

See full
Cash & equivalents$3.5B+78.2%
Total debt$39.4M-8.6%
Total equity$5.6B+53.3%
Total assets$7.3B+27.7%

Cash flow

See full
Operating cash flow$369.4M+38.8%
CapEx$1.6M-43.5%
Free cash flow$367.7M+39.7%

Valuation

See full
Market cap$19.78B+59.9%
Enterprise value$16.35B+55.9%
P/E13.8×-568×
P/S3.7×+0.9×

Profitability

See full
Gross margin92.5%-0.2pp
Operating margin30%+26.1pp
Net margin26.7%+26.2pp

Returns & leverage

See full
Return on equity30.8%+30.4pp
Debt / equity0.0×
Current ratio3.7×+1.6×

Where this comes from

Calculated from Incyte’s reported figures.

Based on the most recent quarter.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's price / book?
Incyte (INCY) reported price / book of 3.3× in Q1 2026.
How has Incyte's price / book changed year-over-year?
Incyte's price / book increased by 4.3% year-over-year, from 3.2× to 3.3×.
What is the long-term trend for Incyte's price / book?
Over 4 years (2021 to 2025), Incyte's price / book has grown at a -11.2% compound annual growth rate (CAGR), from 22× to 13.7×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.